The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).

THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.

To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.

By clicking on the "Accept" button below, you will be deemed to have made this confirmation.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

Fresenius today successfully placed bonds with a volume of €750 million. The bonds have a maturity of 7.5 years and an annual coupon of 1.625%. The issue price is 99.021% and the resulting yield amounts to 1.766%.

The proceeds will be used for general corporate purposes, including refinancing of existing financial liabilities.

The bonds were drawn under the Fresenius European Medium Term Note (EMTN) Program and issued by Fresenius SE & Co. KGaA.

Fresenius has applied to the Luxembourg Stock Exchange to admit the bonds to trading on its regulated market.

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (03, 82 KB)

Fresenius Medical Care, the world’s leading provider of dialysis products and services, postpones its 2020 Annual General Meeting, which was scheduled for May 19, to a later date this year due to the coronavirus pandemic. The resolutions regarding the allocation of the distributable profit and the payout of the dividend will be postponed accordingly.

As soon as conditions allow again for a reliable planning and safe implementation of the Annual General Meeting, Fresenius Medical Care will announce the new date.

Rice Powell, Chief Executive Officer of Fresenius Medical Care, said: “The decision to postpone our Annual General Meeting was not an easy one for us to take. But the protection and health of our shareholders and employees is very important to us. In light of this exceptional situation, a postponement is the only sensible option.”

• New date will be specified and communicated as soon as reliable planning is possible
• Health and safety of shareholders and employees is our priority

Due to the coronavirus pandemic, Fresenius SE & Co. KGaA postpones its Annual General Meeting scheduled for 20 May 2020 to a later date within the current financial year. As one of the consequences, this will lead to a postponement of the resolutions regarding the appropriation of net income 2019 and the payout of the dividend. The Company will set and communicate a new date as soon as the conditions for reliable planning and safe execution of the Annual General Meeting are once again in place.

“At present, the primary task is to slow down the spread of the coronavirus and thus to contain it as far as possible. With this decision, we are also supporting this common goal. The health and safety of our shareholders and employees have highest priority,” said Stephan Sturm, CEO of Fresenius.

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 99 KB)

• New date will be specified and communicated as soon as reliable planning is possible
• Health and safety of shareholders and employees is our priority

Due to the coronavirus pandemic, Fresenius SE & Co. KGaA postpones its Annual General Meeting scheduled for 20 May 2020 to a later date within the current financial year. As one of the consequences, this will lead to a postponement of the resolutions regarding the appropriation of net income 2019 and the payout of the dividend. The Company will set and communicate a new date as soon as the conditions for reliable planning and safe execution of the Annual General Meeting are once again in place.

“At present, the primary task is to slow down the spread of the coronavirus and thus to contain it as far as possible. With this decision, we are also supporting this common goal. The health and safety of our shareholders and employees have highest priority,” said Stephan Sturm, CEO of Fresenius.

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 108 KB)

• Helios Germany is increasing number of intensive care beds by two thirds
• Law to ease financial burden on hospitals likely to offset large part of sales losses and cost increases
• Digital healthcare offerings facilitate continuous medical care for chronically ill and rehabilitation patients

Helios Germany, Germany’s largest private hospital operator and part of the Fresenius Group, is undertaking comprehensive measures to combat the COVID-19 pandemic. In accordance with the German government’s request, surgical procedures are being delayed whenever medically justifiable. The freed-up capacity is reserved for the imminent treatment of COVID-19 patients. Postponed operations should be performed later this year and next. In parallel, Helios Germany will increase the number of ICU beds in its network by two-thirds, from 900 to more than 1,500. This will be accomplished by deploying centrally held equipment reserves across its network as well as by selectively upgrading intermediate care beds and converting operation theatres with already installed ventilator systems.

In order to utilize the incremental capacity most effectively, Helios Germany has selectively adjusted shift models and is prepared to deploy specialist staff across its network to hospitals with particular needs.
Helios Germany is closely monitoring its inventories of important hospital supplies – including disinfectants and protective clothing – and building additional reserves.

Stephan Sturm, CEO of Fresenius, said: “Society is facing very challenging weeks and months ahead. Commitment, sound judgement and close cooperation will all be needed to contain the spread of the coronavirus. At the same time, the best possible care must be provided to patients. Our deepest thanks go to doctors, nurses and care personnel, whether they work at Fresenius or elsewhere: They are needed more than ever, and show tremendous dedication day after day. As a healthcare Group we have a special responsibility in this situation. We must, and we will, meet this responsibility.”

To ease the financial burden on the country’s hospitals during the COVID-19 pandemic, Germany’s Federal Ministry of Health submitted earlier this week a draft law, which was passed by the Bundestag on Wednesday. Among its key provisions:

• Compensation payment of €560 per foregone treatment day compared to 2019.
• Reimbursement of care costs with a flat-rate payment of at least €185 per treatment day.
• Reimbursement of increased costs for protective clothing and other supplies with a flat-rate payment of €50 per patient.
• Public health insurers will settle all treatment invoices in 2020 within five days.
• Significant reduction of health insurers’ (MDK) audit quota and abolition of minimum fines for this year and 2021.
• Co-investment of €50,000 for each new intensive care bed; costs above this amount may be reimbursed by individual state governments.

Fresenius Helios generally welcomes these measures. Assuming the pandemic substantially subsides by the summer, management currently estimates that the financial impact on Helios Germany in 2020, although negative, will not be very significant.

Dr. Francesco De Meo, CEO of Fresenius Helios, said: “It is our approach to combine ethically responsible care for our patients with a high degree of efficiency. To this end, we have invested heavily in our clinics, in our medical technology and also in strengthening our staff in recent years. This is paying off now. The close networking of our hospitals gives us the necessary flexibility to deploy personnel and materials exactly where patients need them most. And we gain insights very swiftly by sharing experiences with our colleagues, through the European exchange that is embedded in Fresenius‘ global network. We are therefore ideally positioned in the joint fight against COVID-19.”

Fresenius is committed to the care of patients with a high infection risk. Given the current treatment restrictions and infection risks, there are significant challenges for the chronically ill to visit local medical practices and get the treatment and support they need. Particularly for these patients, digital healthcare offerings can be a suitable alternative. Following its acquisition of Digitale Gesundheitsgruppe, Fresenius’ subsidiary Curalie now offers an even wider range of digital healthcare services for patients with chronic illnesses such as diabetes, kidney disease and heart disease, through to rehabilitation patients in orthopedic aftercare. For the duration of the current COVID-19 pandemic, Curalie will make its digital healthcare services available free of charge. Thus, Fresenius and Curalie are helping to ensure continuous medical care to these vulnerable patients.

• Helios Germany is increasing number of intensive care beds by two thirds
• Law to ease financial burden on hospitals likely to offset large part of sales losses and cost increases
• Digital healthcare offerings facilitate continuous medical care for chronically ill and rehabilitation patients

Helios Germany, Germany’s largest private hospital operator and part of the Fresenius Group, is undertaking comprehensive measures to combat the COVID-19 pandemic. In accordance with the German government’s request, surgical procedures are being delayed whenever medically justifiable. The freed-up capacity is reserved for the imminent treatment of COVID-19 patients. Postponed operations should be performed later this year and next. In parallel, Helios Germany will increase the number of ICU beds in its network by two-thirds, from 900 to more than 1,500. This will be accomplished by deploying centrally held equipment reserves across its network as well as by selectively upgrading intermediate care beds and converting operation theatres with already installed ventilator systems.

In order to utilize the incremental capacity most effectively, Helios Germany has selectively adjusted shift models and is prepared to deploy specialist staff across its network to hospitals with particular needs.

Helios Germany is closely monitoring its inventories of important hospital supplies – including disinfectants and protective clothing – and building additional reserves.

Stephan Sturm, CEO of Fresenius, said: “Society is facing very challenging weeks and months ahead. Commitment, sound judgement and close cooperation will all be needed to contain the spread of the coronavirus. At the same time, the best possible care must be provided to patients. Our deepest thanks go to doctors, nurses and care personnel, whether they work at Fresenius or elsewhere: They are needed more than ever, and show tremendous dedication day after day. As a healthcare Group we have a special responsibility in this situation. We must, and we will, meet this responsibility.”

To ease the financial burden on the country’s hospitals during the COVID-19 pandemic, Germany’s Federal Ministry of Health submitted earlier this week a draft law, which was passed by the Bundestag on Wednesday. Among its key provisions:

• Compensation payment of €560 per foregone treatment day compared to 2019.
• Reimbursement of care costs with a flat-rate payment of at least €185 per treatment day.
• Reimbursement of increased costs for protective clothing and other supplies with a flat-rate payment of €50 per patient.
• Public health insurers will settle all treatment invoices in 2020 within five days.
• Significant reduction of health insurers’ (MDK) audit quota and abolition of minimum fines for this year and 2021.
• Co-investment of €50,000 for each new intensive care bed; costs above this amount may be reimbursed by individual state governments.

Fresenius Helios generally welcomes these measures. Assuming the pandemic substantially subsides by the summer, management currently estimates that the financial impact on Helios Germany in 2020, although negative, will not be very significant.

Dr. Francesco De Meo, CEO of Fresenius Helios, said: “It is our approach to combine ethically responsible care for our patients with a high degree of efficiency. To this end, we have invested heavily in our clinics, in our medical technology and also in strengthening our staff in recent years. This is paying off now. The close networking of our hospitals gives us the necessary flexibility to deploy personnel and materials exactly where patients need them most. And we gain insights very swiftly by sharing experiences with our colleagues, through the European exchange that is embedded in Fresenius‘ global network. We are therefore ideally positioned in the joint fight against COVID-19.”

Fresenius is committed to the care of patients with a high infection risk. Given the current treatment restrictions and infection risks, there are significant challenges for the chronically ill to visit local medical practices and get the treatment and support they need. Particularly for these patients, digital healthcare offerings can be a suitable alternative. Following its acquisition of Digitale Gesundheitsgruppe, Fresenius’ subsidiary Curalie now offers an even wider range of digital healthcare services for patients with chronic illnesses such as diabetes, kidney disease and heart disease, through to rehabilitation patients in orthopedic aftercare. For the duration of the current COVID-19 pandemic, Curalie will make its digital healthcare services available free of charge. Thus, Fresenius and Curalie are helping to ensure continuous medical care to these vulnerable patients.

With virtually all of Fresenius Kabi’s manufacturing staff in China returning to work post government-imposed COVID-19 quarantine restrictions, the company is ramping-up production back to normal levels. With a further stabilization of the situation, Fresenius Kabi also expects a gradual resumption of its sales force activities in China. Even though Fresenius Kabi faced challenges due to the COVID-19 pandemic and the quarantine measures, there was no major interruption of production. Thus, the company can supply the Chinese population with essential pharmaceuticals and medical devices.

With virtually all of Fresenius Kabi’s manufacturing staff in China returning to work post government-imposed COVID-19 quarantine restrictions, the company is ramping-up production back to normal levels. With a further stabilization of the situation, Fresenius Kabi also expects a gradual resumption of its sales force activities in China. Even though Fresenius Kabi faced challenges due to the COVID-19 pandemic and the quarantine measures, there was no major interruption of production. Thus, the company can supply the Chinese population with essential pharmaceuticals and medical devices.

Contact

Head of Corporate Communications
T +49 (0) 6172 608-96008
pr-fre@fresenius.com

Documents

Text as PDF document (PDF, 104 KB)

• All Quirónsalud hospitals are fully operational and managed by Quirónsalud in close coordination with the health authorities
• Rumors about a “nationalization” are without any basis

Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, is fully committed to supporting the national effort against COVID-19 with all available resources. Since the start of the crisis, Quirónsalud has worked in close and trustful cooperation with national and regional healthcare authorities to provide the best possible treatment to the greatest possible number of patients.

Quirónsalud’s network currently comprises about 400 ICU beds for adults in almost 50 hospitals across Spain. The company is undertaking significant efforts to further increase this number in the short term, while continuing to treat other patients who urgently need medical support such as for chemotherapy, giving birth, and other emergencies.

Despite the high number of suspected and confirmed COVID-19 cases entering Quirónsalud’s hospitals, the company has kept every hospital fully operational. This is to a large extent due to the outstanding commitment of Quirónsalud’s medical and nursing staff, who deserve the utmost recognition and gratitude. So far, Quirónsalud has also been able to secure sufficient quantities of medical materials for all its hospitals, despite rapidly rising demand for critical supplies.

In the course of the formal declaration of a ‘State of Alarm’, the Spanish government has temporarily obtained the right to direct all hospitals in the country, allowing the healthcare authorities to leverage all available resources to treat COVID-19 patients as effectively as possible. Such an option is embedded in the established crisis management plans of many other European countries as well. Quirónsalud fully supports this measure, as it allows centralized capacity management, and hence rapid responses to changing circumstances and a full dedication of the entire system to fight the coronavirus.

Rumors about a “nationalization” of Spain’s private hospital system are clearly wrong and without any basis. Quirónsalud continues to manage its hospitals, and is already operating the additional beds requested by the authorities, in the joint effort against the COVID-19 threat for the benefit of Spain and the broader society.